Marlotamig is named as an intervention in 3 current clinical trials in our USA register. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is Regeneron Pharmaceuticals. The most-studied condition is Advanced Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
NCT07154290 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
|
Phase 2 | Recruiting | Regeneron Pharmaceuticals | USA |
|
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
|
Phase 2 | Active, closed | Regeneron Pharmaceuticals | USA |
|
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
|
Phase 1/2 | Active, closed | Regeneron Pharmaceuticals | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Regeneron Pharmaceuticals | 3 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our USA register name Marlotamig (also registered as REGN7075) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in USA. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Regeneron Pharmaceuticals. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Marlotamig works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Marlotamig works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Marlotamig (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.